Angus G. Jones

6.9k total citations · 3 hit papers
77 papers, 3.1k citations indexed

About

Angus G. Jones is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Surgery. According to data from OpenAlex, Angus G. Jones has authored 77 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Endocrinology, Diabetes and Metabolism, 40 papers in Genetics and 39 papers in Surgery. Recurrent topics in Angus G. Jones's work include Diabetes Management and Research (46 papers), Diabetes and associated disorders (39 papers) and Pancreatic function and diabetes (35 papers). Angus G. Jones is often cited by papers focused on Diabetes Management and Research (46 papers), Diabetes and associated disorders (39 papers) and Pancreatic function and diabetes (35 papers). Angus G. Jones collaborates with scholars based in United Kingdom, United States and Uganda. Angus G. Jones's co-authors include Andrew T. Hattersley, Beverley M. Shields, Timothy J. McDonald, John Dennis, Richard A. Oram, Bridget Knight, William Henley, Anita Hill, Michael N. Weedon and Rachel Besser and has published in prestigious journals such as The Lancet, Nature Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Angus G. Jones

74 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The clinical utility of C‐peptide measurement in the care of patients with diabetes

2013 439 citations Angus G. Jones, Andrew T. Hattersley Diabetic Medicine profile →
Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data

2019 282 citations John Dennis, Beverley M. Shields et al. profile →
Adult-Onset Type 1 Diabetes: Current Understanding and Challenges

2021 132 citations Angus G. Jones et al. Diabetes Care profile →

Peers

Countries citing papers authored by Angus G. Jones

Since Specialization

Citations

This map shows the geographic impact of Angus G. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angus G. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angus G. Jones more than expected).

Fields of papers citing papers by Angus G. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angus G. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angus G. Jones. The network helps show where Angus G. Jones may publish in the future.

Co-authorship network of co-authors of Angus G. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Angus G. Jones. A scholar is included among the top collaborators of Angus G. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angus G. Jones. Angus G. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection 2025 ·Diabetologia ·(unknown), Katherine Young, (unknown), Andrew McGovern, Beverley M. Shields, Andrew T. Hattersley, Angus G. Jones, Ewan R. Pearson, Coralie Bingham, Richard A. Oram, John Dennis	1
2	Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach 2024 ·Diabetologia ·(unknown), (unknown), Nicholas J. Thomas, (unknown), Robert Challen, Angus G. Jones, Andrew T. Hattersley, Ewan R. Pearson, Beverley M. Shields, Jack Bowden, John Dennis, Andrew McGovern	9
3	Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes 2024 ·Diabetologia ·(unknown), Katherine Young, Anand Thakarakkattil Narayanan Nair, (unknown), Andrew McGovern, Eram Haider, (unknown), Louise A. Donnelly, Bilal A. Mateen, Naveed Sattar, Rury R. Holman, Jack Bowden, Andrew T. Hattersley, Ewan R. Pearson, Angus G. Jones, Beverley M. Shields, Trevelyan J. McKinley, John Dennis	12
4	The Maturity-Onset Diabetes of the Young (MODY) Calculator Overestimates MODY Probability in Hispanic Youth 2024 ·The Journal of Clinical Endocrinology & Metabolism ·(unknown), Anh Minh Nguyen, Angus G. Jones, Beverley M. Shields, María J. Redondo, Mustafa Tosur	1
5	Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors 2023 ·medRxiv ·Katherine Young, (unknown), Robert Massey, (unknown), Scott J. Pilla, (unknown), Maggie A. Stanislawski, Deirdre K. Tobias, Andrew McGovern, Adem Y. Dawed, Angus G. Jones, Ewan R. Pearson, John Dennis	2
6	Islet Autoantibody Level Distribution in Type 1 Diabetes and Their Association With Genetic and Clinical Characteristics 2022 ·The Journal of Clinical Endocrinology & Metabolism ·Sian Grace, Jack Bowden, Helen C. Walkey, (unknown), Shivani Misra, Beverley M. Shields, Trevelyan J. McKinley, Nick Oliver, Timothy J. McDonald, Desmond G. Johnston, Angus G. Jones, Kashyap Patel	8
7	Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study 2022 ·Nature Medicine ·Beverley M. Shields, John Dennis, (unknown), Fiona C Warren, William Henley, Andrew Farmer, Naveed Sattar, Rury R. Holman, Angus G. Jones, Ewan R. Pearson, Andrew T. Hattersley, (unknown)	27
8	The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis 2022 ·Diabetologia ·Katherine Young, Andrew McGovern, Inês Barroso, Andrew T. Hattersley, Angus G. Jones, Beverley M. Shields, Nicholas J. Thomas, John Dennis	4
9	Identifying type 1 and 2 diabetes in research datasets where classification biomarkers are unavailable: assessing the accuracy of published approaches 2022 ·Journal of Clinical Epidemiology ·Nicholas J. Thomas, Andrew McGovern, Katherine Young, Seth A. Sharp, Michael N. Weedon, Andrew T. Hattersley, John Dennis, Angus G. Jones	14
10	Understanding the pathogenesis of lean non-autoimmune diabetes in an African population with newly diagnosed diabetes 2022 ·Diabetologia ·Davis Kibirige, (unknown), (unknown), Angus G. Jones, Andrew T. Hattersley, Liam Smeeth, Moffat Nyirenda	31
11	Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study 2022 ·Nature Medicine ·Beverley M. Shields, (unknown), Maggie Shepherd, Nicky Britten, Angus G. Jones, Naveed Sattar, Rury R. Holman, Ewan R. Pearson, Andrew T. Hattersley	8
12	Continuous glucose monitoring demonstrates low risk of clinically significant hypoglycemia associated with sulphonylurea treatment in an African type 2 diabetes population: results from the OPTIMAL observational multicenter study 2022 ·BMJ Open Diabetes Research & Care ·(unknown), Lauren R. Rodgers, Alice L. J. Carr, (unknown), Raymond Mwebaze, Andrew T. Hattersley, Beverley M. Shields, Moffat Nyirenda, Angus G. Jones	3
13	Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes 2021 ·Diabetes Care ·Angus G. Jones, Timothy J. McDonald, Beverley M. Shields, William Hagopian, Andrew T. Hattersley	56
14	HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: the OPTIMAL observational multicenter study 2021 ·BMJ Open Diabetes Research & Care ·(unknown), Lauren R. Rodgers, (unknown), (unknown), Raymond Mwebaze, Timothy J. McDonald, Andrew T. Hattersley, Beverley M. Shields, Moffat Nyirenda, Angus G. Jones	4
15	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation 2020 ·BMJ Open Diabetes Research & Care ·Andrew McGovern, Michael A. Hogg, Beverley M. Shields, Naveed Sattar, Rury R. Holman, Ewan R. Pearson, Andrew T. Hattersley, Angus G. Jones, John Dennis	62
16	TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol 2020 ·BMJ Open ·(unknown), Caroline Jenkinson, Angus G. Jones, Christopher Jennison, William Henley, Andrew Farmer, Naveed Sattar, Rury R. Holman, Ewan R. Pearson, Beverley M. Shields, Andrew T. Hattersley	13
17	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017 2019 ·Diabetes Obesity and Metabolism ·John Dennis, William Henley, Andrew McGovern, Andrew Farmer, Naveed Sattar, Rury R. Holman, Ewan R. Pearson, Andrew T. Hattersley, Beverley M. Shields, Angus G. Jones	68
18	Persistent C‐peptide is associated with reduced hypoglycaemia but not HbA_1c in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice? 2019 ·Diabetic Medicine ·(unknown), S. Hammersley, Timothy J. McDonald, Beverley M. Shields, Bridget Knight, Anita Hill, (unknown), Timothy Tree, Bart O. Roep, Andrew T. Hattersley, Angus G. Jones, Richard A. Oram	27
19	Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18–50 years 2019 ·BMJ Open ·Anita L. Lynam, Timothy J. McDonald, Anita Hill, John Dennis, Richard A. Oram, Ewan R. Pearson, Michael N. Weedon, Andrew T. Hattersley, Katharine R. Owen, Beverley M. Shields, Angus G. Jones	44
20	A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody–Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy 2018 ·Diabetes Care ·(unknown), Timothy J. McDonald, Femke Rutters, Louise A. Donnelly, Andrew T. Hattersley, Richard A. Oram, (unknown), Amber A. van der Heijden, Fiona Carr, Petra J. M. Elders, Michael N. Weedon, Roderick C. Slieker, Leen M. ‘t Hart, Ewan R. Pearson, Beverley M. Shields, Angus G. Jones	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact